vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and WOLFSPEED, INC. (WOLF). Click either name above to swap in a different company.

WOLFSPEED, INC. is the larger business by last-quarter revenue ($168.5M vs $168.4M, roughly 1.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -6.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -8.4%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Wolfspeed, Inc. is an American developer and manufacturer of wide-bandgap semiconductors, focused on silicon carbide materials and devices for power applications such as transportation, power supplies, power inverters, and wireless systems. The company was formerly named Cree, Inc.

ESPR vs WOLF — Head-to-Head

Bigger by revenue
WOLF
WOLF
1.0× larger
WOLF
$168.5M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+150.4% gap
ESPR
143.7%
-6.6%
WOLF
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
-8.4%
WOLF

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ESPR
ESPR
WOLF
WOLF
Revenue
$168.4M
$168.5M
Net Profit
$-150.6M
Gross Margin
-46.5%
Operating Margin
50.6%
-94.0%
Net Margin
-89.4%
Revenue YoY
143.7%
-6.6%
Net Profit YoY
59.5%
EPS (diluted)
$0.32
$-5.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
WOLF
WOLF
Q4 25
$168.4M
$168.5M
Q3 25
$87.3M
$196.8M
Q2 25
$82.4M
$197.0M
Q1 25
$65.0M
$185.4M
Q4 24
$69.1M
$180.5M
Q3 24
$51.6M
$194.7M
Q2 24
$73.8M
$200.7M
Q1 24
$137.7M
$200.7M
Net Profit
ESPR
ESPR
WOLF
WOLF
Q4 25
$-150.6M
Q3 25
$-31.3M
$-643.6M
Q2 25
$-12.7M
$-669.3M
Q1 25
$-40.5M
$-285.5M
Q4 24
$-372.2M
Q3 24
$-29.5M
$-282.2M
Q2 24
$-61.9M
$-174.9M
Q1 24
$61.0M
$-148.9M
Gross Margin
ESPR
ESPR
WOLF
WOLF
Q4 25
-46.5%
Q3 25
-39.2%
Q2 25
-13.0%
Q1 25
-12.1%
Q4 24
-20.6%
Q3 24
-18.6%
Q2 24
1.2%
Q1 24
11.2%
Operating Margin
ESPR
ESPR
WOLF
WOLF
Q4 25
50.6%
-94.0%
Q3 25
-11.4%
-82.0%
Q2 25
8.6%
-295.2%
Q1 25
-34.0%
-104.9%
Q4 24
-6.4%
-178.9%
Q3 24
-31.0%
-118.2%
Q2 24
3.5%
-72.7%
Q1 24
52.5%
-53.0%
Net Margin
ESPR
ESPR
WOLF
WOLF
Q4 25
-89.4%
Q3 25
-35.9%
-327.0%
Q2 25
-15.4%
-339.7%
Q1 25
-62.2%
-154.0%
Q4 24
-206.2%
Q3 24
-57.2%
-144.9%
Q2 24
-83.9%
-87.1%
Q1 24
44.3%
-74.2%
EPS (diluted)
ESPR
ESPR
WOLF
WOLF
Q4 25
$0.32
$-5.78
Q3 25
$-0.16
$-4.12
Q2 25
$-0.06
$-4.42
Q1 25
$-0.21
$-1.86
Q4 24
$-0.14
$-2.88
Q3 24
$-0.15
$-2.23
Q2 24
$-0.33
$-1.39
Q1 24
$0.34
$-1.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
WOLF
WOLF
Cash + ST InvestmentsLiquidity on hand
$167.9M
$1.3B
Total DebtLower is stronger
$2.0B
Stockholders' EquityBook value
$-302.0M
$627.4M
Total Assets
$465.9M
$3.4B
Debt / EquityLower = less leverage
3.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
WOLF
WOLF
Q4 25
$167.9M
$1.3B
Q3 25
$92.4M
$926.0M
Q2 25
$86.1M
$955.4M
Q1 25
$114.6M
$1.3B
Q4 24
$144.8M
$1.4B
Q3 24
$144.7M
$1.7B
Q2 24
$189.3M
$2.2B
Q1 24
$226.6M
$2.6B
Total Debt
ESPR
ESPR
WOLF
WOLF
Q4 25
$2.0B
Q3 25
$0
Q2 25
$6.5B
Q1 25
$6.5B
Q4 24
$6.4B
Q3 24
$6.2B
Q2 24
$6.2B
Q1 24
Stockholders' Equity
ESPR
ESPR
WOLF
WOLF
Q4 25
$-302.0M
$627.4M
Q3 25
$-451.4M
$-1.1B
Q2 25
$-433.5M
$-447.1M
Q1 25
$-426.2M
$212.7M
Q4 24
$-388.7M
$372.6M
Q3 24
$-370.2M
$628.9M
Q2 24
$-344.2M
$882.1M
Q1 24
$-294.3M
$1.0B
Total Assets
ESPR
ESPR
WOLF
WOLF
Q4 25
$465.9M
$3.4B
Q3 25
$364.0M
$6.6B
Q2 25
$347.1M
$6.9B
Q1 25
$324.0M
$7.6B
Q4 24
$343.8M
$7.7B
Q3 24
$314.1M
$7.9B
Q2 24
$352.3M
$8.0B
Q1 24
$373.1M
$7.7B
Debt / Equity
ESPR
ESPR
WOLF
WOLF
Q4 25
3.13×
Q3 25
Q2 25
Q1 25
30.61×
Q4 24
17.24×
Q3 24
9.81×
Q2 24
6.98×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
WOLF
WOLF
Operating Cash FlowLast quarter
$45.2M
$-42.6M
Free Cash FlowOCF − Capex
$-72.6M
FCF MarginFCF / Revenue
-43.1%
Capex IntensityCapex / Revenue
0.0%
17.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-988.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
WOLF
WOLF
Q4 25
$45.2M
$-42.6M
Q3 25
$-4.3M
$5.7M
Q2 25
$-31.4M
$-242.5M
Q1 25
$-22.6M
$-142.1M
Q4 24
$-35.0M
$-195.1M
Q3 24
$-35.3M
$-132.0M
Q2 24
$-7.2M
$-239.5M
Q1 24
$53.8M
$-136.2M
Free Cash Flow
ESPR
ESPR
WOLF
WOLF
Q4 25
$-72.6M
Q3 25
$-98.3M
Q2 25
$-454.4M
Q1 25
$-362.8M
Q4 24
$-596.9M
Q3 24
$-35.5M
$-569.0M
Q2 24
$-7.3M
$-883.8M
Q1 24
$53.8M
$-713.7M
FCF Margin
ESPR
ESPR
WOLF
WOLF
Q4 25
-43.1%
Q3 25
-49.9%
Q2 25
-230.7%
Q1 25
-195.7%
Q4 24
-330.7%
Q3 24
-68.7%
-292.2%
Q2 24
-9.9%
-440.4%
Q1 24
39.0%
-355.6%
Capex Intensity
ESPR
ESPR
WOLF
WOLF
Q4 25
0.0%
17.8%
Q3 25
0.0%
52.8%
Q2 25
0.0%
107.6%
Q1 25
0.0%
119.0%
Q4 24
0.0%
222.6%
Q3 24
0.3%
224.4%
Q2 24
0.1%
321.0%
Q1 24
0.1%
287.7%
Cash Conversion
ESPR
ESPR
WOLF
WOLF
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

WOLF
WOLF

Power Products$118.3M70%
Materials Products$50.2M30%

Related Comparisons